Critical Challenges Require Core Values - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Critical Challenges Require Core Values
Industry has changed, but its basic tenets have not. INTERPHEX's RJ Palermo discusses a 7-step process to keep pharma moving forward.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 12


RJ Palermo
The pharmaceutical industry is facing many changes but its core values remain the same. Those values are aimed at creating new opportunities to enrich lives and heal bodies.

In the longterm, how much industry progresses will depend on how well academia, pharmaceutical companies, and the government work together on some basic principles. This collaboration boils down to a recent talk by Biotechnology Industry Organization CEO Jim Greenwood at the BioNJ 2009 Annual Meeting. The 7-step process he described is outlined below.

1) Provide progressive funding , starting with the National Institutes of Health to carry out stem cell research. This research can open up new opportunities for cures.

2) Protect patents. Innovation spurs breakthroughs and saves lives, especially in the biotechnology industry where patent protection is critical to attracting private funding.

3) Support start-ups. Grants and funding for venture-backed biotechnology companies allow these drugmakers to use accounting rules for small companies and keep innovation alive during expensive research phases.

4) Encourage investment. Tax policy that favors investment allows companies to accelerate new treatments.

5) Maintain belief in the US Food and Drug Administration. We need to provide FDA with the resources it needs to review, assess, and approve effective drugs in a timely manner.

6) Increase access. By creating sound reimbursement policies, individuals can better benefit from breakthrough therapies.

7) Ensure safety. Understanding the risks and benefits of drug products, and sharing that information, allows patients to make the best decisions about their treatment.

These long-term steps can help to eliminate pressures faced today by pharmaceutical and biopharmaceutical companies. Challenges such as expiring patents, profit decline, global economic meltdown, and trends toward personalized medicine are changing the ways drugs are produced. Take, for example, process analytical technology, quality by design, and the Product Quality Life Cycle Implementation initiative that the International Society for Pharmacetuical Engineering is driving. With basic principles in tact and supported, drug products will be able to be manufactured more cost effectively without sacrificing quality.

At the same time, different parts of the industry need to collaborate more. Current outsourcing trends already point to increased relationships among equipment suppliers, information technology companies, contract research and manufacturing organizations, engineers, architects, validators, and consulting firms. An integrated approach is vital to producing the most effective and safe drugs.

For our industry, everything is moving at a much faster pace despite the economic downturn.


INTERPHEX 2009
INTERPHEX 2009 (see details below) will allow pharmaceutical and biopharmaceutical professionals to experience new learning to keep up with these changes. This year's show features more than 70 conference sessions, 900 exhibitors showing some 1600 product lines and 200-plus new technologies. Let's celebrate as industry gathers to discuss producing the next medicines that will enrich lives.

RJ Palermo is industry vice-president for INTERPHEX 2009, tel. 203.850.5924,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here